Amelioration of inflammatory bowel disease by Bifidobacterium animalis subsp. lactis XLTG11 in combination with mesalazine

The treatment of inflammatory bowel disease (IBD) remains challenging and significantly impacts both patients and their families. This study evaluated the role of Bifidobacterium animalis subsp. lacti XLTG11 (XLTG11) in combination with mesalazine (5-ASA) in the improvement of IBD. The results demon...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Weiwei Ma, Yanan Wu, Xinyue Lin, Liping Yang, Lili Huang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-12-01
Edice:	Frontiers in Microbiology
Témata:	Bifidobacterium animalis subsp. lacti mesalazine IBD intestinal microorganisms SCAFs
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fmicb.2024.1472776/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!